Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ARA 290 in no-option critical limb ischemia
NL-OMON34878Phase 2Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing ARA 290 with Placebo (2 arms). Primary endpoints: Wound healing, Pedal pain and 1 more. Planned start May 2010; status: withdrawn.
02
Drugs
cibinetide
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NL-OMON34878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34878.